...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Enthusiasm? NOT!

,,,Not sure how much accuarcy is in what DMcC tells us in this or any presentation...but if its true that these BPs are actually involved with our science as per the slides one would think we would have news on a variation of deals,,one would think!,,,,but par for this company as well, he wished to have news ready to present that should be positive,,odd statement!!!,,,well if he doesnt know if the news is positive it tells of his ability to assess value or importance. Nothing advancing on the business side as expected, so shareholders are out of luck once again as noted by rocketman2. Its certainly a sleepy hollow investment. Nothing has changed for us since 2013,,,,,,what will 2033 possibly hold,,,,,if we are alive to witness any of it.

Share
New Message
Please login to post a reply